Virtus ETF Advisers’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Virtus ETF Advisers’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,220	Closed	-$263K	–	191
2016 Q4	$263K	Buy	+7,220	New	+$255K	0.08%	128

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Virtus ETF Advisers's CLCD Position: Q1 2017 in Review

Virtus ETF Advisers sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 7,220 shares — an estimated $263K sold.

Virtus ETF Advisers first reported a position in CLCD in Q4 2016 and held it in 1 quarter. The position peaked at $263K in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Virtus ETF Advisers reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Virtus ETF Advisers sold 7,220 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $263K.
Virtus ETF Advisers first reported a position in CoLucid Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
Virtus ETF Advisers's CoLucid Pharmaceuticals, Inc. position peaked at $263K in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Virtus ETF Advisers's 13F filing for Q1 2017, filed 15 May 2017.